Treatment of idiopathic pulmonary fibrosis with autologous adult bone marrow stem cells

Vera S.T. · Revista Cubana de Hematologia, Inmunologia y Hemoterapia (2022)

Resumen

Introduction: Idiopathic pulmonary fibrosis represents a degenerative disease with a dire prognosis, whose therapeutic options are very limited, so it is necessary to evaluate alternatives available to the population. Objective: To evaluate treatment with autologous adult bone marrow (BM) stem cells in a 68-year-old patient with a radiological diagnosis of pulmonary fibrosis and dyspnea at rest. Case presentation: The patient attended the consultation with dyspnea at rest, and digital saturation of 74%, which after her first intravenous treatment with adult bone marrow stem cells, achieved significant improvement, with saturations ranging between 85 and 90% at 4 months after the first therapy. Eight months after the first session, she received a second dose, with which she increased the saturation to values between 94 and 97%, three weeks after the latter. Conclusion: Conclusion: Treatment with autologous adult bone marrow stem cells could improve the signs and symptoms of patients with idiopathic pulmonary fibrosis.